Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn
Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4…
The Economic Times ·